Newsbenzinga
Ultragenyx Nabs FDA Nod for First Gene Therapy
· Published
Article summary
Ultragenyx shares rise after FDA approval of Genglycos, with a $2.7 million wholesale cost and $362 million peak sales estimate.
An excerpt from the original article.
Comments —
Loading comments…